B-CELL MALIGNANCY
Clinical trials for B-CELL MALIGNANCY explained in plain language.
Never miss a new study
Get alerted when new B-CELL MALIGNANCY trials appear
Sign up with your email to follow new studies for B-CELL MALIGNANCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
CRISPR breakthrough: new 'Off-the-Shelf' cell therapy fights tough blood cancers
Disease control Recruiting nowThis study is testing a new type of cell therapy called CTX112 for people with B-cell blood cancers that have come back or not responded to other treatments. Doctors use CRISPR gene-editing technology to modify donor immune cells to better target and fight the cancer. The main go…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for Tough-to-Treat blood cancers: trial tests Next-Gen drug
Disease control Recruiting nowThis study is testing a new oral medication called BGB-16673 for people with various B-cell cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe and effective dose and to see how well the drug shrinks tumors. It is for adults …
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
New hope for tough blood cancers: testing a powerful drug cocktail
Disease control Recruiting nowThis study is testing the safety and early effectiveness of a new drug, BGB-16673, when given with other cancer medicines. It is for people whose B-cell cancers, like certain lymphomas, have returned or stopped responding to previous treatments. The trial will test four different…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New pill tested for tough blood cancers after other treatments fail
Disease control Recruiting nowThis study is testing a new oral medication called AS-1763 for adults with certain blood cancers that have returned or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see if the drug helps control the cancer. The trial will enroll a…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1 • Sponsor: Carna Biosciences, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New 'Off-the-Shelf' cancer treatment trial offers hope for patients who have run out of options
Disease control Recruiting nowThis early-phase study is testing a new type of cell therapy called universal CAR-T (UWD-CD19) for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to standard treatments. The goal is to see if this 'off-the-shelf' therapy, made from donor…
Matched conditions: B-CELL MALIGNANCY
Phase: EARLY_PHASE1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC